Patents by Inventor Deepak Phadke

Deepak Phadke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly purified pharmaceutical grade tasimelteon
    Patent number: 10611744
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 7, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 10233142
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 19, 2019
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON
    Publication number: 20190002423
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
  • Highly purifid pharmaceutical grade tasimelteon
    Patent number: 10071977
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: September 11, 2018
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Deepak Phadke, Natalie M Platt, Ravi K Pandrapragada
  • MELATONIN AGONIST TREATMENT
    Publication number: 20180243258
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Inventors: Gunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMIDE
    Publication number: 20180099924
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 12, 2018
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9850199
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 26, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • HIGHLY PURIFID PHARMACEUTICAL GRADE TASIMELTEON
    Publication number: 20170190683
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Application
    Filed: February 12, 2015
    Publication date: July 6, 2017
    Inventors: Deepak PHADKE, Natalie M PLATT
  • METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMIDE
    Publication number: 20170174617
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 22, 2017
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9617203
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 11, 2017
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • MELATONIN AGONIST TREATMENT
    Publication number: 20160354337
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Gunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMIDE
    Publication number: 20160060212
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 3, 2016
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
    Patent number: 9212129
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 15, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMIDE
    Publication number: 20150148419
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • MELATONIN AGONIST TREATMENT
    Publication number: 20150080464
    Abstract: Melatonin Agonist, MA-1, is administered at effective doses.
    Type: Application
    Filed: November 27, 2014
    Publication date: March 19, 2015
    Inventors: Gunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20150045390
    Abstract: R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Deepak Phadke, Curt D. Wolfgang, Mihael H. Polymeropoulos, John Joseph Feeney, Gunther Birznieks
  • Stable dosage formulations of imidazolylalkyl-pyridines
    Patent number: 8865210
    Abstract: Stable formulations of imidazolylalkyl-pyridines, including controlled-release formulations.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: October 21, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian N. Lavedan, Deepak Phadke
  • USE OF A MELATONIN AGONIST FOR THE TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY INSOMNIA
    Publication number: 20120136050
    Abstract: Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form.
    Type: Application
    Filed: July 16, 2010
    Publication date: May 31, 2012
    Applicant: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Gunther Birznieks, Deepak Phadke
  • TREATMENT FOR DEPRESSIVE DISORDERS
    Publication number: 20090209638
    Abstract: A method of treating depression comprising administering a melatonin agonist.
    Type: Application
    Filed: May 22, 2007
    Publication date: August 20, 2009
    Inventors: Gunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
  • MELATONIN AGONIST TREATMENT
    Publication number: 20090105333
    Abstract: This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.
    Type: Application
    Filed: May 22, 2007
    Publication date: April 23, 2009
    Inventors: Gunther Birznieks, Deepak Phadke, Mihael H. Polymeropoulos